glp-1 colitis GLP-1s and Ulcerative Colitis: Safety and Provider Guidance – PlexusDx GLP-1 based therapies and disease

Higher doses and longer duration of GLP-1 RAs treatment were also associated with increased risk of gallbladder or biliary diseases, although the association was not statistically significant

Critical Considerations: This schedule is purely theoretical and not based on clinical evidence Individual tolerance varies dramaticallysome may not tolerate even these conservative doses Maximum combined doses would likely need to remain below monotherapy maximums (perhaps 2.4 mg cagrilintide + 8 mg retatrutide as absolute ceiling) Medical supervision would be essential throughout any such protocol Alternative Approach: Sequential Rather Than Concurrent An arguably safer alternative to simultaneous cagrilintide dosage with retatrutide administration involves sequential optimization: Optimize one compound first Reach stable, effective dose of either cagrilintide or retatrutide Assess response Evaluate metabolic effects over 12-16 weeks Introduce second compound Only if additional effects are needed Ultra-gradual second titration Even slower escalation of the added compound Continuous reassessment Regular evaluation of whether combination provides benefits beyond monotherapy This approach provides clearer attribution of effects and side effects to specific compounds, though it significantly extends the overall timeline

Yan Y, Gong Y, Jiang M, Gao Y, Guo S, Huo J, et al

& Smith, A

Key [moisturizing] ingredients include ceramides, hyaluronic acid, squalane, glycerin, and niacinamide. He adds that retinol has the potential to boost collagen production, thereby firming the skin on the face and body